No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
BEAM241220P36000
- 0.00
- 0.000.00%
15min DelayTrading Dec 12 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest36.00Strike Price0.00Turnover164.22%IV-30.20%PremiumDec 20, 2024Expiry Date8.35Intrinsic Value100Multiplier8DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.8261Delta0.0381Gamma3.16Leverage Ratio-0.1043Theta-0.0059Rho-2.61Eff Leverage0.0106Vega
Intraday
- 5D
- Daily
No Data
News
Editas Cut to Equal Weight by Wells Fargo Over Reni-cel Positioning
Why Beam Therapeutics (BEAM) Is the Worst ARK Stock to Buy According to Short Sellers
A Quick Look at Today's Ratings for Beam Therapeutics(BEAM.US), With a Forecast Between $42 to $80
Beam Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Beam Therapeutics Analyst Ratings
Promising Early Data and Innovative Approaches Lead to Buy Rating for Beam Therapeutics